Forte Biosciences (FBRX) Competitors

$20.07 -0.90 (-4.29%)

Closing price 04:00 PM Eastern

Extended Trading

$20.05 -0.02 (-0.12%)

As of 04:10 PM Eastern

FBRX vs. AVBP, CRVS, GHRS, WVE, and MLTX

Should you buy Forte Biosciences stock or one of its competitors? MarketBeat compares Forte Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Forte Biosciences include ArriVent BioPharma (AVBP), Corvus Pharmaceuticals (CRVS), GH Research (GHRS), WAVE Life Sciences (WVE), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry.

How does Forte Biosciences compare to ArriVent BioPharma?

Forte Biosciences (NASDAQ:FBRX) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

Forte Biosciences currently has a consensus target price of $67.00, suggesting a potential upside of 233.83%. ArriVent BioPharma has a consensus target price of $42.78, suggesting a potential upside of 63.59%. Given Forte Biosciences' higher possible upside, equities analysts plainly believe Forte Biosciences is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92

77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 4.4% of Forte Biosciences shares are held by insiders. Comparatively, 8.6% of ArriVent BioPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ArriVent BioPharma's return on equity of -48.98% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-106.17%	-85.50%
ArriVent BioPharma	N/A	-48.98%	-45.44%

In the previous week, Forte Biosciences had 2 more articles in the media than ArriVent BioPharma. MarketBeat recorded 12 mentions for Forte Biosciences and 10 mentions for ArriVent BioPharma. Forte Biosciences' average media sentiment score of 0.86 beat ArriVent BioPharma's score of -0.34 indicating that Forte Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forte Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ArriVent BioPharma	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

ArriVent BioPharma is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

Forte Biosciences has a beta of 3.01, suggesting that its stock price is 201% more volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.51, suggesting that its stock price is 51% more volatile than the broader market.

Summary

Forte Biosciences and ArriVent BioPharma tied by winning 7 of the 14 factors compared between the two stocks.

How does Forte Biosciences compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

Corvus Pharmaceuticals has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Forte Biosciences has a beta of 3.01, meaning that its stock price is 201% more volatile than the broader market.

Corvus Pharmaceuticals' return on equity of -38.92% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%
Forte Biosciences	N/A	-106.17%	-85.50%

Corvus Pharmaceuticals presently has a consensus target price of $33.33, indicating a potential upside of 189.86%. Forte Biosciences has a consensus target price of $67.00, indicating a potential upside of 233.83%. Given Forte Biosciences' higher probable upside, analysts clearly believe Forte Biosciences is more favorable than Corvus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A

46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 19.7% of Corvus Pharmaceuticals shares are owned by insiders. Comparatively, 4.4% of Forte Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Corvus Pharmaceuticals had 7 more articles in the media than Forte Biosciences. MarketBeat recorded 19 mentions for Corvus Pharmaceuticals and 12 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 0.86 beat Corvus Pharmaceuticals' score of -0.07 indicating that Forte Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Forte Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Corvus Pharmaceuticals beats Forte Biosciences on 8 of the 13 factors compared between the two stocks.

How does Forte Biosciences compare to GH Research?

Forte Biosciences (NASDAQ:FBRX) and GH Research (NASDAQ:GHRS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

GH Research's return on equity of -19.36% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-106.17%	-85.50%
GH Research	N/A	-19.36%	-18.73%

77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 56.9% of GH Research shares are held by institutional investors. 4.4% of Forte Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

GH Research is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A

Forte Biosciences has a beta of 3.01, suggesting that its stock price is 201% more volatile than the broader market. Comparatively, GH Research has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market.

Forte Biosciences presently has a consensus target price of $67.00, suggesting a potential upside of 233.83%. GH Research has a consensus target price of $40.38, suggesting a potential upside of 84.02%. Given Forte Biosciences' higher possible upside, analysts clearly believe Forte Biosciences is more favorable than GH Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, Forte Biosciences had 5 more articles in the media than GH Research. MarketBeat recorded 12 mentions for Forte Biosciences and 7 mentions for GH Research. Forte Biosciences' average media sentiment score of 0.86 beat GH Research's score of -0.48 indicating that Forte Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forte Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GH Research	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Forte Biosciences beats GH Research on 7 of the 13 factors compared between the two stocks.

How does Forte Biosciences compare to WAVE Life Sciences?

Forte Biosciences (NASDAQ:FBRX) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

Forte Biosciences has higher earnings, but lower revenue than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A
WAVE Life Sciences	$42.73M	27.65	-$204.38M	-$1.06	N/A

In the previous week, Forte Biosciences had 5 more articles in the media than WAVE Life Sciences. MarketBeat recorded 12 mentions for Forte Biosciences and 7 mentions for WAVE Life Sciences. Forte Biosciences' average media sentiment score of 0.86 beat WAVE Life Sciences' score of 0.00 indicating that Forte Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forte Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
WAVE Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Forte Biosciences has a beta of 3.01, meaning that its stock price is 201% more volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.32, meaning that its stock price is 232% less volatile than the broader market.

Forte Biosciences has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -255.70%. WAVE Life Sciences' return on equity of -56.76% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-106.17%	-85.50%
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 4.4% of Forte Biosciences shares are held by company insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Forte Biosciences currently has a consensus price target of $67.00, indicating a potential upside of 233.83%. WAVE Life Sciences has a consensus price target of $27.19, indicating a potential upside of 342.79%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe WAVE Life Sciences is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

Summary

WAVE Life Sciences beats Forte Biosciences on 9 of the 15 factors compared between the two stocks.

How does Forte Biosciences compare to MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Forte Biosciences is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A

In the previous week, MoonLake Immunotherapeutics and MoonLake Immunotherapeutics both had 12 articles in the media. Forte Biosciences' average media sentiment score of 0.86 beat MoonLake Immunotherapeutics' score of 0.48 indicating that Forte Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Forte Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MoonLake Immunotherapeutics' return on equity of -85.15% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%
Forte Biosciences	N/A	-106.17%	-85.50%

93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are held by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Comparatively, 4.4% of Forte Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

MoonLake Immunotherapeutics currently has a consensus target price of $23.85, suggesting a potential upside of 45.67%. Forte Biosciences has a consensus target price of $67.00, suggesting a potential upside of 233.83%. Given Forte Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Forte Biosciences is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.38
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

MoonLake Immunotherapeutics has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market. Comparatively, Forte Biosciences has a beta of 3.01, meaning that its stock price is 201% more volatile than the broader market.

Summary

MoonLake Immunotherapeutics beats Forte Biosciences on 7 of the 12 factors compared between the two stocks.

Get Forte Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FBRX vs. The Competition

Export

Metric	Forte Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$278.77M	$3.25B	$6.25B	$12.10B
Dividend Yield	N/A	2.33%	2.80%	5.32%
P/E Ratio	-4.33	18.70	20.58	25.11
Price / Sales	N/A	278.20	577.42	91.32
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	4.26	6.57	9.68	6.60
Net Income	-$69.38M	$24.30M	$3.55B	$335.71M
7 Day Performance	-17.37%	-3.56%	-2.07%	-2.03%
1 Month Performance	-40.83%	-7.86%	-3.90%	-1.90%
1 Year Performance	167.60%	51.80%	29.39%	27.36%

Forte Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FBRX Forte Biosciences	2.3301 of 5 stars	$20.07 -4.3%	$67.00 +233.8%	+167.1%	$278.77M	N/A	N/A	5	Upcoming Earnings Analyst Upgrade
AVBP ArriVent BioPharma	2.6037 of 5 stars	$28.97 -0.2%	$43.00 +48.4%	+39.7%	$1.34B	N/A	N/A	40	Gap Down
CRVS Corvus Pharmaceuticals	2.0982 of 5 stars	$15.97 +1.0%	$33.33 +108.7%	+238.2%	$1.34B	N/A	N/A	30	Trending News Analyst Revision
GHRS GH Research	2.8814 of 5 stars	$21.54 +1.3%	$40.13 +86.3%	+97.4%	$1.34B	N/A	N/A	10	Earnings Report Analyst Forecast
WVE WAVE Life Sciences	2.2934 of 5 stars	$6.79 -4.0%	$27.50 +305.0%	+1.1%	$1.31B	$42.73M	N/A	240	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FBRX) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Forte Biosciences (FBRX) Competitors

FBRX vs. AVBP, CRVS, GHRS, WVE, and MLTX

How does Forte Biosciences compare to ArriVent BioPharma?

Summary

How does Forte Biosciences compare to Corvus Pharmaceuticals?

Summary

How does Forte Biosciences compare to GH Research?

Summary

How does Forte Biosciences compare to WAVE Life Sciences?

Summary

How does Forte Biosciences compare to MoonLake Immunotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBRX vs. The Competition

Forte Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Forte Biosciences (FBRX) Competitors

FBRX vs. AVBP, CRVS, GHRS, WVE, and MLTX

How does Forte Biosciences compare to ArriVent BioPharma?

Do analysts prefer FBRX or AVBP?

Do institutionals and insiders hold more shares of FBRX or AVBP?

Is FBRX or AVBP more profitable?

Does the media refer more to FBRX or AVBP?

Which has better earnings and valuation, FBRX or AVBP?

Which has more volatility & risk, FBRX or AVBP?

Summary

How does Forte Biosciences compare to Corvus Pharmaceuticals?

Which has more risk & volatility, CRVS or FBRX?

Is CRVS or FBRX more profitable?

Do analysts rate CRVS or FBRX?

Which has higher valuation and earnings, CRVS or FBRX?

Do insiders & institutionals have more ownership in CRVS or FBRX?

Does the media favor CRVS or FBRX?

Summary

How does Forte Biosciences compare to GH Research?

Is FBRX or GHRS more profitable?

Do institutionals and insiders believe in FBRX or GHRS?

Which has preferable valuation & earnings, FBRX or GHRS?

Which has more volatility & risk, FBRX or GHRS?

Do analysts prefer FBRX or GHRS?

Does the media refer more to FBRX or GHRS?

Summary

How does Forte Biosciences compare to WAVE Life Sciences?

Which has better earnings & valuation, FBRX or WVE?

Does the media refer more to FBRX or WVE?

Which has more volatility and risk, FBRX or WVE?

Is FBRX or WVE more profitable?

Do institutionals and insiders have more ownership in FBRX or WVE?

Do analysts recommend FBRX or WVE?

Summary

How does Forte Biosciences compare to MoonLake Immunotherapeutics?

Which has stronger earnings and valuation, MLTX or FBRX?

Does the media prefer MLTX or FBRX?

Is MLTX or FBRX more profitable?

Do institutionals & insiders believe in MLTX or FBRX?

Do analysts rate MLTX or FBRX?

Which has more volatility and risk, MLTX or FBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBRX vs. The Competition

Forte Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools